METTL2B

Across TCGA pan-cancer cohorts, METTL2B RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of METTL2B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where METTL2B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types METTL2B is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

KIRP, LIHC, and KIRC are the cancer types where METTL2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in METTL2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	IV	+1.014	<.001	9	view →
LIHC	Female	II,III,IV	+0.872	<.001	9	view →
KIRC	All	All	+0.265	<.001	9	view →
COAD	Male	All	+0.740	<.001	8	view →
LUAD	Male	II,III,IV	+0.649	<.001	8	view →
HNSC	All	IV	+0.541	<.001	8	view →
STAD	All	II,III,IV	+0.699	<.001	6	view →
BLCA	All	All	+0.440	.005	5	view →
LUSC	Male	All	+0.374	<.001	4	view →
CHOL	Male	All	+1.640	<.001	3	view →
THCA	All	All	−0.176	.008	3	view →
READ	All	All	+0.761	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

METTL2B–KIRP

Open the KIRP breakdown →